Connect With Our Dedicated

VALUE & ACCESS TEAM

Discover the potential economic value of using CUROSURF® (poractant alfa) with an early rescue strategy

The Impact of Early Rescue

Evaluate how early rescue with exogenous surfactants* may impact your institution

Predicting CPAP failure may potentially decrease exposure to mechanical ventilation in preterm infants.1 While predictors include birth weight, gestational age, CPAP level, and FiO2 level, multiple studies have shown that FiO2 is the strongest predictor of CPAP failure.2-4

If your hospital has implemented a Quality Improvement (QI) program, you may want to consider the cost implications of standard surfactant administration versus early rescue surfactant administration as it relates to clinical outcomes.

Our dedicated Value & Access team may be able to help you navigate internal discussions related to CUROSURF, including but not limited to the following areas:

  • Quality measures and improvement initiatives
  • Cost consequence modeling
  • Pharmacoeconomic data from clinical trials
  • Tools to navigate the formulary review process

*Exogenous surfactants are not indicated for the prevention of bronchopulmonary dysplasia (BPD).

Get in touch with the Value & Access team today

To be connected to a Value & Access Specialist, provide your preferred contact information. If you have specific topics you would like to focus on, please select from the options below (selection is optional).



All fields are required unless otherwise indicated.

(optional)





Health economic and value information can be provided to a payor, formulary committee, or other similar entity with knowledge and expertise in the area of healthcare economic analysis, carrying out its responsibilities for the selection of drugs for coverage or reimbursement. For more information, please contact us.healtheconomics@chiesi.com.

Please see the CUROSURF Full Prescribing Information.

CUROSURF Home
MEDICAL INFORMATION

To request specific medical information about CUROSURF or to report adverse events or product complaints, contact the Medical Information Department.

Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-1088.

Mail:
Chiesi USA, Inc.
175 Regency Woods Place
Suite 600
Cary, NC 27518

Web:
https://chiesiusamedical.com/

Phone:
1-888-661-9260

Fax:
1-866-443-3092

CONTACT CHIESI USA, INC.

Mail:
Chiesi USA, Inc.
175 Regency Woods Place
Suite 600
Cary, NC 27518

Email:
us.contact@chiesi.com

Phone:
1-888-661-9260

IMPORTANT SAFETY INFORMATION

CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.

CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.

Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.

Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).

INDICATION

CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

Please see Full Prescribing Information.

References: 1. Yao W, et al. J Pediatr Pharmacol Ther. 2022;27(8):695-702. 2. Dargaville PA, et al. Neonatology. 2013;104(1):8-14. 3. Gulczynska E,Szczapa T, Hozejowski R, Borszewska-Kornacka MK, Rutkowska M. Neonatology. 2019;116:171-178.4. Kakkilaya V, Wagner S, Mangona KLM, et al. J Perinatol. 2019;39:1081-88.